Australia - English - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - hydrocortisone, quantity: 2 mg - granules - excipient ingredients: microcrystalline cellulose; hypromellose; magnesium stearate; ethylcellulose - replacement therapy of adrenal insufficiency

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd -

Australia - English - Department of Health (Therapeutic Goods Administration)

mindray medical australia pty ltd - 40770 - transducer assembly, ultrasound, diagnostic, intracorporeal, surgical - a hand-held ultrasound imaging transducer assembly designed to be positioned within a surgical site for localized intraoperative imaging applications. it is sometimes referred to as a surgical probe or fingertip probe. it steers, focuses, and detects the ultrasound beam and resulting echoes either mechanically or electronically. this ultrasound imaging transducer is used with a-mode, b-mode, m-mode, doppler, colour doppler (cd), and duplex (combination imaging, doppler and/or colour flow) scanning capabilities. this is a reusable device.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - atorvastatin calcium, quantity: 41.44 mg (equivalent: atorvastatin, qty 40 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; povidone; methionine; magnesium stearate; crospovidone; sodium carbonate; mannitol; purified talc; titanium dioxide; hypromellose; macrogol 6000 - an adjunct to diet for the treatment of patients with hypercholesterolaemia. . prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated. . atorvastatin is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - atorvastatin calcium, quantity: 20.72 mg (equivalent: atorvastatin, qty 20 mg) - tablet, film coated - excipient ingredients: povidone; microcrystalline cellulose; crospovidone; sodium carbonate; mannitol; methionine; magnesium stearate; purified talc; titanium dioxide; hypromellose; macrogol 6000 - an adjunct to diet for the treatment of patients with hypercholesterolaemia. . prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated. . atorvastatin is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - atorvastatin calcium, quantity: 20.72 mg (equivalent: atorvastatin, qty 20 mg) - tablet, film coated - excipient ingredients: purified talc; mannitol; crospovidone; povidone; sodium carbonate; magnesium stearate; methionine; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 6000 - an adjunct to diet for the treatment of patients with hypercholesterolaemia. . prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated. . atorvastatin is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - atorvastatin calcium, quantity: 10.36 mg (equivalent: atorvastatin, qty 10 mg) - tablet, film coated - excipient ingredients: sodium carbonate; povidone; magnesium stearate; crospovidone; purified talc; mannitol; microcrystalline cellulose; methionine; titanium dioxide; hypromellose; macrogol 6000 - an adjunct to diet for the treatment of patients with hypercholesterolaemia. . prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated. . atorvastatin is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - atorvastatin calcium, quantity: 10.36 mg (equivalent: atorvastatin, qty 10 mg) - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; methionine; mannitol; microcrystalline cellulose; purified talc; sodium carbonate; povidone; titanium dioxide; hypromellose; macrogol 6000 - an adjunct to diet for the treatment of patients with hypercholesterolaemia. . prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated. . atorvastatin is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

United States - English - NLM (National Library of Medicine)

avaria health & beauty corp - methyl salicylate (unii: lav5u5022y) (salicylic acid - unii:o414pz4lpz), levomenthol (unii: bz1r15mtk7) (levomenthol - unii:bz1r15mtk7), camphor (synthetic) (unii: 5tjd82a1et) (camphor (synthetic) - unii:5tjd82a1et) - topical analgesic penetrating pain relief for the temporary relief of minor aches and pains of muscle and joint pain associated with arthritis, backache, strains, sprains and bruises.

Australia - English - Department of Health (Therapeutic Goods Administration)

swisse wellness pty ltd - agathosma betulina,crateva nurvala,galium aparine,vaccinium macrocarpon,zea mays -